Pharsight

Epi Hlth patents expiration

1. Minolira patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103517 EPI HLTH Pharmaceutical compositions for minocycline
Apr, 2036

(12 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

MINOLIRA family patents

Family Patents

2. Rhofade patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
Jan, 2024

(3 months from now)

US8420688 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
Aug, 2024

(10 months from now)

US7812049 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
May, 2028

(4 years from now)

US8883838 EPI HLTH Pharmaceutical cream compositions and methods of use
Dec, 2031

(8 years from now)

US11517560 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US9974773 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US10751325 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US10335391 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 January, 2017

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with ...

Dosage: CREAM;TOPICAL

How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage

RHOFADE family patents

Family Patents

3. Sitavig patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791127 EPI HLTH Mucosal bioadhesive slow release carrier for delivering active principles
Mar, 2027

(3 years from now)

US8747896 EPI HLTH Mucosal bioadhesive slow release carrier for delivering active principles
Jun, 2027

(3 years from now)

US8592434 EPI HLTH Mucoadhesive buccal tablets for the treatment of orofacial herpes
Jun, 2030

(6 years from now)

Drugs and Companies using ACYCLOVIR ingredient

Market Authorisation Date: 12 April, 2013

Treatment: Treatment of herpes labialis

Dosage: TABLET;BUCCAL

More Information on Dosage

SITAVIG family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic